INTRODUCTION
============

Metabolic acidosis arises from a fundamental disturbance of acid--base balance and is common in patients with chronic kidney disease (CKD). Optimal cell, tissue and organ function requires the maintenance of hydrogen ion (H^+^) concentration within a physiologic range, which for serum is 35--45 nM (pH 7.46--7.35). The dynamic process leading to a net gain of H^+^ in body fluids is called acidosis. When acidosis is due to a gain of 'fixed acid' H^+^ (as opposed to the gain of 'volatile' H^+^ because of accumulation of carbon dioxide gas, causing respiratory acidosis) and this H^+^ gain decreases the metabolic component of the acid--base equilibrium, bicarbonate (HCO~3~), it is called metabolic acidosis. If the amount or rate of added H^+^ exceeds normal excretory capacity or if H^+^ excretory capacity is reduced as in CKD with reduced glomerular filtration rate (GFR), metabolic acidosis becomes chronic. Epidemiological studies show that the prevalence of metabolic acidosis is approximately 15--19% in CKD stage 3--5 patients, with metabolic acidosis affecting approximately 3 million patients with CKD in the United States \[[@R1]--[@R4]\].

The relationship between decreasing serum HCO~3~ levels and worsening clinical outcomes appears to be a continuum. As serum HCO~3~ decreases from the normal range in patients with CKD, generally considered as 22--29 mEq/l \[[@R5],[@R6]\], the risk of progression to end-stage kidney disease (ESKD) or mortality increases compared to patients with CKD but without metabolic acidosis \[[@R7]--[@R11],[@R12],[@R13],[@R14]\]. Indeed, observational studies associate serum HCO~3~ with kidney disease progression outcomes and show that each 1 mEq/l increase in serum HCO~3~ from levels below the normal range reduces the risk of kidney outcomes \[e.g., initiation of dialysis, 50% reduction in estimated glomerular filtration rate (eGFR)\] by 3--8% \[[@R7]--[@R11],[@R12]\]. Interestingly, risk reduction continues for serum HCO~3~ increases within the low normal range \[[@R9]\]. Findings from these observational studies are supported by recent prospective interventional studies that show that treatment of metabolic acidosis in CKD stage 3--5 patients can slow the rate of kidney function decline \[[@R15],[@R16]^▪▪^,[@R17],[@R18]^▪▪^,[@R19]\]. In addition, provision of sodium bicarbonate or a diet rich in base-producing fruits and vegetables to CKD stage 3 patients with serum HCO~3~ in the low normal range (22--24 mEq/l) also slowed the rate of kidney function decline \[[@R20]\]. Post hoc analysis of treatment effect in CKD stage 3--5 patients with overt metabolic acidosis (serum HCO~3~ \<22 mEq/l) \[[@R17]\] showed that fewer patients treated with oral alkali supplementation, in comparison to untreated patients, reached at least 40% eGFR reduction, an endpoint recognized to be a validated surrogate endpoint for ESKD \[[@R21]--[@R25]\]. Thus, data from these prospective studies suggest the intriguing possibility that interventions that increase or normalize serum HCO~3~ in patients with CKD and metabolic acidosis or low normal serum HCO~3~ may further slow deterioration of the diseased kidney. 
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INCREASING SERUM BICARBONATE SLOWS PROGRESSION OF CHRONIC KIDNEY DISEASE
========================================================================

Five studies have examined the impact of metabolic acidosis treatment with oral alkali or base-producing dietary interventions on the progression of kidney disease in CKD stage 3--5 patients with reduced serum HCO~3~ (\<22 mEq/l) (Table [1](#T1){ref-type="table"}) \[[@R15],[@R16]^▪▪^,[@R17],[@R18]^▪▪^,[@R19]\]. The study by de Brito-Ashurst *et al*. \[[@R15]\] represented an important first step in linking correction of low serum HCO~3~ and improved outcomes in patients with CKD and metabolic acidosis. In this single-center, open-label, prospective, parallel-group study, 134 CKD stage 4--5 patients with metabolic acidosis (serum HCO~3~ \>16 and \<20 mEq/l) were randomized 1:1 to intervention with oral sodium bicarbonate, administered as 600 mg tablets three times per day and increased as necessary to achieve and maintain serum HCO~3~ at least 23 mEq/l, or standard of care for 2 years. The objectives of the study were to assess the effects of oral sodium bicarbonate therapy on progression of CKD and on nutritional status in these predialysis patients. The study population had an average baseline creatinine clearance of ∼20 ml/min/1.73 m^2^ and an average baseline serum HCO~3~ level of ∼20 mEq/l. Study criteria excluded patients with poorly controlled blood pressure (BP; \>150/90 mmHg, despite use of four agents), overt congestive heart failure, morbid obesity, and chronic sepsis, all conditions with potential fluid balance complications that could be worsened with ingestion of ∼500 mg of sodium that accompanied the average oral sodium bicarbonate daily dose administered in this study (1.82 ± 0.80 g/day). At the end of the 2-year study, serum HCO~3~ increased in the treated patients by approximately 4 mEq/l compared with the control group (Fig. [1](#F1){ref-type="fig"}a); these results were clinically meaningful and statistically significant (*P* \< 0.0001). Compared with the control group, decline in creatinine clearance was slower with sodium bicarbonate supplementation (−1.88 versus −5.93 ml/min/1.73 m^2^; *P* \< 0.0001), a difference of approximately 4 ml/min/1.73 m^2^ over the 2-year treatment period (Fig. [1](#F1){ref-type="fig"}b). Patients who received treatment for their metabolic acidosis were also significantly less likely than controls to experience rapid progression of kidney failure (9 versus 45%; *P* \< 0.0001) or to develop ESKD (6.5 versus 33%; *P* \< 0.001) over the 2-year treatment period (Fig. [2](#F2){ref-type="fig"}). Thus, this landmark study demonstrated the beneficial effects of increasing serum HCO~3~ on slowing the progression of kidney disease to an extent that was both statistically significant and clinically meaningful.

![Serum bicarbonate (HCO~3~) increase and eGFR decline in chronic kidney disease (CKD) patients with metabolic acidosis (serum HCO~3~ \<22 mEq/l) treated with NaHCO~3~ or sodium citrate supplementation versus control. Summary of changes in serum HCO3 (panel a) and estimated glomerular filtration rate (eGFR) decline (panel b) in CKD patients with metabolic acidosis (serum HCO~3~ \<22 mEq/l) treated with NaHCO~3~ or sodium citrate supplementation (active) versus control patients. Data were extracted from the respective studies listed on the x-axis and cited in the reference section \[[@R15],[@R16]^▪▪^,[@R17],[@R18]^▪▪^\]; all values are mean changes from beginning to the end of the treatment period. The mean serum HCO~3~ values at the end of treatment for the de Brito-Ashurst *et al*. \[[@R15]\] study were estimated from graphed data. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; HCO~3~, bicarbonate.](conhy-28-267-g002){#F1}

![Reduction in kidney events in chronic kidney disease (CKD) patients with metabolic acidosis (serum HCO~3~ \<22 mEq/l) treated with NaHCO~3~ supplementation versus control. Summary of the reduction in kidney event rate (panel a) and relative risk reduction for kidney events (panel b) in CKD patients with metabolic acidosis (HCO~3~ \<22 mEq/l) treated with NaHCO~3~ supplementation (active) versus control patients. Data were extracted from the respective studies listed on the x-axis and cited in the Reference section \[[@R15],[@R16]^▪▪^,[@R17],[@R18]^▪▪^\]. Kidney event rate (panel a) was significantly different for active versus control in the de Brito-Ashurst *et al*. \[[@R15]\] (*P* \< 0.001), Garneata *et al*. \[[@R16]^▪▪^\] (*P* \< 0.001), and Dubey *et al*. \[[@R18]^▪▪^\] (*P* = 0.001) studies; the data presented for Phisitkul *et al*. \[[@R17]\] were derived from the patient level data analysis described in Table [3](#T3){ref-type="table"}. CKD, chronic kidney disease; HCO~3~, bicarbonate.](conhy-28-267-g003){#F2}

Dietary interventions that severely limit the amount of acid-producing animal protein or increase the consumption of base-producing fruits and vegetables ameliorate metabolic acidosis, the rate of eGFR decline, and markers of kidney injury \[[@R16]^▪▪^,[@R19],[@R20]\]. A recent study by Garneata *et al*. \[[@R16]^▪▪^\] explored the potential contributions of very low-protein, plant-based diets and ketoanalogue supplementation on nephropathy progression. In this single-center, open-label, prospective, parallel-group study, 207 patients with CKD stage 4--5 and metabolic acidosis were treated for 15 months. One hundred four (104) patients were randomized to receive a vegetarian, ketoanalogue-supplemented, very low-protein diet (VLPD) (0.3 g/kg/day) and the remaining 103 patients served as the control group and received a typical low-protein (from plant and animal sources) diet (LPD) (0.6 g/kg/day). The patient population had a baseline eGFR of ∼18 ml/min/1.73 m^2^ and a serum HCO~3~ of ∼17 mEq/l. Patients with poorly controlled arterial BP (≥145/85 mmHg), diabetes, or heart failure were excluded and only 14% of the screened patients met all the eligibility criteria, agreed to adhere to the dietary requirements, and were randomized in this study. Baseline serum HCO~3~ was similar in the two treatment groups, with median values of 16.7 and 16.8 mEq/l in the VLPD and LPD groups, respectively. However, at the end of study, serum HCO~3~ significantly increased (+6.2 mEq/l) in the VLPD group but slightly decreased (−0.6 mEq/l) in the LPD group, a difference between groups of 6.8 mEq/l (Fig. 1a). The rate of kidney function decline, as measured by eGFR, was slower in patients on the VLPD diet compared to controls on the LPD diet. At the end of the 15-month treatment period, the patients on the VLPD regimen had a −2.9 ml/min/1.73 m^2^ decrease of eGFR relative to their baseline value, whereas patients on the LPD regimen had a −7.1 ml/min/1.73 m^2^ decrease relative to their baseline value, a difference between groups of 4.2 ml/min/1.73 m^2^ (Fig. [1](#F1){ref-type="fig"}b). The mean eGFR at end of study was significantly higher (*P* \< 0.01) in the VLPD group (15.1 ml/min/1.73 m^2^, 95% confidence interval 13.2--17.4) than in the LPD group (10.8 ml/min/1.73 m^2^; 95% confidence interval 9.0--12.2). Patients eating the VLPD diet were significantly less likely (*P* \< 0.001) than LPD controls to meet the primary endpoint of kidney replacement therapy or a decrease in eGFR of more than 50% (13 versus 42%; VLPD and LPD, respectively) over the 15-month intervention period (Fig. [2](#F2){ref-type="fig"}).

The study by Phisitkul *et al.*\[[@R17]\] was designed to examine the treatment effect of oral sodium citrate on the rate of eGFR decline in CKD stage 3--4 patients with metabolic acidosis, in addition to determining the effects on four biomarkers of kidney injury, including urine endothelin-1 (a surrogate of kidney endothelin production that mediates progressive kidney injury), urine N-acetyl−β-D-glucosaminidase (NAG; a marker of kidney tubulointerstitial injury), urine albumin (a general marker of progressive kidney injury), and urine transforming growth factor β (TGF-β; a general marker of progressive kidney injury) \[[@R25]--[@R30]\]. The study was a single-center, open-label, prospective, parallel-group study of 59 patients with hypertension-associated nephropathy and metabolic acidosis. Patients were treated for 6 months with antihypertensive drug regimens including angiotensin-converting enzyme inhibitors to control their BP, and then were assigned to treatment for metabolic acidosis with oral sodium citrate (1 mEq/kg bicarbonate equivalent daily in three divided doses; *N* = 30) or no treatment (*N* = 29) for 2 years. The 29 patients serving as controls were unable or unwilling to take sodium citrate. The population of study patients had a baseline mean eGFR value of ∼33 ml/min/1.73 m^2^ and mean serum HCO~3~ of ∼20 mEq/l. At the end of the 2-year treatment period, mean (± SE) serum HCO~3~ levels had increased significantly (+3.3 mEq/l) in sodium citrate-treated patients but had decreased significantly (−0.9 mEq/l) in untreated patients; the difference between the treated and untreated groups (4.2 mEq/l) was also significantly different (*P* \< 0.0001) at the end of the treatment period (Fig. [1](#F1){ref-type="fig"}a). Comparisons using linear mixed models demonstrated that the yearly rate of eGFR decline was significantly slower in the sodium citrate-treated group compared with the no treatment group. The comparison between treatment and no treatment was −1.60 ± 0.13 versus −3.79 ± 0.30 ml/min/year (*P* \< 0.0001), respectively, when eGFR was calculated using plasma creatinine values, and −1.82 ± 0.08 versus −4.38 ± 0.98 ml/min/year (*P* \< 0.0001), respectively, when eGFR was calculated using plasma cystatin C values. In addition to slowing kidney decline, treatment of metabolic acidosis with sodium citrate was also associated with significant decreases in the urine biomarkers of kidney injury (endothelin-1, NAG, albumin, and TGF-β).

The benefits of oral alkali treatment in the control of metabolic acidosis may be realized in a short course of therapy. A recent study by Dubey *et al.*\[[@R18]^▪▪^\] examined the effect of sodium bicarbonate administration over a 6-month period in acidotic patients with stage 3--4 CKD, with respect to changes from baseline in lean body mass (LBM), mid-arm muscle circumference (MAMC), and eGFR. The study was a single-center, open-label, prospective, parallel-group study of 188 patients with a stable eGFR, defined as less than 5% fluctuations during a 4-week preenrollment observation period. Patients with CKD of unidentified cause (CKDu) were included in the study, as previously defined \[[@R31]\], and CKDu was the most common cause of CKD in the enrolled patients (52.1%). Patients with decompensated chronic liver disease, decompensated heart failure, and morbid obesity were excluded from the study. The patients were assigned to standard of care and oral sodium bicarbonate (2.3 g/day; intervention arm; *N* = 94;) or standard of care only (control arm; *N* = 94). The population of study patients had a baseline mean eGFR value of ∼30 ml/min/1.73 m^2^ and mean serum HCO~3~ of ∼18 mEq/l. At the end of the 6-month treatment period, mean serum HCO~3~ levels increased significantly (+5.4 mEq/l) in treated patients but decreased (−0.3 mEq/l) in untreated patients, a difference between groups of 5.7 mEq/l (Fig. [1](#F1){ref-type="fig"}a). The intervention arm showed an increase in eGFR by 2.4 ml/min/1.73 m^2^, whereas the eGFR in the control arm decreased by −2.3 ml/min/1.73 m^2^ (Fig. [1](#F1){ref-type="fig"}b). A rapid decline in eGFR (defined as \>3 ml/min/1.73 m^2^) was seen in 41.5% of the control patients versus 20.2% of the treatment patients (*P* = 0.001) (Fig. [2](#F2){ref-type="fig"}). In addition, the intervention group showed significantly increased LBM index and MAMC versus the control group. It is important to note that the intervention group had a significantly increased requirement for diuretics (35.1%) versus the control group (18.1%) (*P* = 0.008), along with worsening hypertension and edema, but this latter trend did not reach significance. Overall, adverse effects (excluding increases in diuretic prescriptions and hospitalizations; all hospitalizations were due to acute kidney injury) were higher in the treatment group (77.7%) versus the control group (41.4%) (*P* = 0.01). This short-term (6 month) study using oral alkali to treat metabolic acidosis in patients with CKD suggested that the course of treatment could preserve LBM, MAMC, and kidney function, but came at the expense of increased sodium intake and the increased requirement for diuretics in a population of patients already prone to sodium-sensitive comorbidities.

A series of studies compared the effects of dietary base-producing fruits and vegetables with those of oral sodium bicarbonate in the control of serum HCO~3~ and rate of eGFR decline in CKD patients with metabolic acidosis (serum HCO~3~ \<22 mEq/l) or low normal (22--24 mEq/l) serum HCO~3~. In the first of these studies by Goraya *et al.*\[[@R19]\], patients with stage 4 CKD because of hypertension-associated nephropathy and serum HCO~3~ \<22 mEq/l were assigned to either a diet with added base-producing fruits and vegetables or 1 mEq/kg/day sodium bicarbonate. The fruits and vegetables were provided in sufficient quantity to reduce dietary acid by 50%, calculated from 3-day diaries of daily food intake. The primary outcome measure was the change in eGFR, with secondary outcomes related to plasma and urine acid--base measures and markers of kidney injury. Estimated GFR was not different between the sodium bicarbonate and fruits and vegetables groups after the 1-year treatment. However, metabolic acidosis, as measured by an increase in serum HCO~3~, was significantly improved in both groups (*P* \< 0.01). Similarly, 8-h net acid excretion was significantly lower in both treatment groups (*P* \< 0.01), with a larger effect observed in the oral sodium bicarbonate group compared with the fruits and vegetables group (*P* \< 0.01). Both interventions were associated with lower-than-baseline urine indices of kidney injury, including albumin, NAG, and TGF-β.

A more recent study \[[@R20]\] enrolled CKD stage 3 patients with hypertension-associated nephropathy (eGFR 30--59 ml/min/1.73 m^2^) and low normal serum HCO~3~ (22--24 mEq/l), a level higher than that for which kidney disease outcomes quality initiative (KDOQI) and kidney disease improving global outcomes (KDIGO) recommend treatment \[[@R5],[@R6]\]. The primary outcome measure was the change from baseline in eGFR after 3 years of treatment with oral sodium bicarbonate or an added fruits and vegetables diet that was designed to reduce dietary acid by 50% (achieved with an average dose of 25.2 mEq/day or 2.1 g/day of sodium bicarbonate, or with the necessary amounts of fruits and vegetables, guided by 3-day food intake diaries to calculate potential dietary acid load); these interventions were compared with a usual care group which received no additional bicarbonate supplementation. At the end of the 3-year treatment period, mean serum HCO~3~ was significantly higher in the patients receiving oral sodium bicarbonate (24.0 ± 0.6 versus 23.1 ± 0.6 mEq/l baseline; *P* \< 0.01) or fruits and vegetables (23.9 ± 0.6 versus 23.0 ± 0.6 mEq/l baseline; *P* \< 0.01) and significantly lower in patients who received usual care (22.4 ± 0.6 versus 23.0 ± 0.5 mEq/l baseline; *P* \< 0.01). Mean creatinine eGFR and cystatin C eGFR decreased over the 3-year treatment period in all three treatment groups, but the decrease from baseline to year 2 and from baseline to year 3 was significantly less in the oral sodium bicarbonate and fruits and vegetables groups than in the usual care group (*P* \< 0.05). In addition, treatments with oral sodium bicarbonate and fruits and vegetables were both associated with significant decreases (*P* \< 0.05) in three markers of kidney damage over the 3-year treatment period, including urinary albumin, NAG, and urine angiotensinogen, a surrogate of kidney angiotensin II levels that has been associated with progressive kidney injury. These results suggest that dietary acid reduction is kidney protective in CKD patients with metabolic acidosis and serum HCO~3~ in the low normal range and higher than that for which current treatment guidelines recommend alkali therapy.

As shown above, treatments that increase serum HCO~3~ in CKD stage 3--5 patients with metabolic acidosis or low-normal serum HCO~3~ demonstrate significant slowing of CKD progression. Early stage CKD patients (e.g., CKD stage 2) without apparent decreases in serum HCO~3~ may nonetheless have compensatory responses to nonvolatile acid accumulation that might promote kidney injury \[[@R32],[@R33]\]. To test the potential benefit of therapy to reduce H^+^ retention in these early stage CKD patients, hypertension-associated nephropathy patients with reduced but relatively preserved eGFR (∼75 ml/min/1.73 m^2^) and serum HCO~3~ in the normal range (∼26 mEq/l) were studied by Mahajan *et al.*\[[@R34]\] to evaluate whether sodium bicarbonate could reduce the rate of eGFR decline in this patient population receiving adequate BP control. Comparisons using linear mixed models demonstrated that the rate of eGFR decline was significantly lower in the oral sodium bicarbonate treatment group (−1.47 ± 0.19 ml/min/year) compared to the sodium chloride (−2.05 ± 0.19 ml/min/year; *P* = 0.029) treatment group and the placebo group (−2.13 ± 0.19 ml/min/year; *P* = 0.014). Overall, this study demonstrated that oral alkali therapy slowed the rate of eGFR decline in early-stage hypertensive nephropathy patients with reduced but relatively preserved eGFR.

The combined findings of the studies summarized above indicate that alkali supplementation, in the form of oral bicarbonate or dietary modification, in patients with CKD and metabolic acidosis (serum HCO~3~ \<22 mEq/l) or low normal serum HCO~3~ (22--24 mEq/l) can preserve kidney function. A tabular summary of the studies is provided in Table [1](#T1){ref-type="table"}. It is important to note that in these studies, patients with CKD and common sodium-sensitive comorbidities, such as heart failure, edema, and uncontrolled hypertension, were excluded as a precaution considering the added sodium load of oral alkali supplementation and increased potassium intake accompanying a fruits and vegetable, vegetarian-based diet.

ADDITIONAL ANALYSIS RELATING SERUM BICARBONATE INCREASE AND REDUCTION OF ESTIMATED GLOMERULAR FILTRATION RATE DECLINE IN PATIENTS TREATED WITH ORAL BICARBONATE SUPPLEMENTATION
===============================================================================================================================================================================

The findings of the above prospective studies and the association of better kidney outcomes with treatment of metabolic acidosis in CKD suggest a promising new approach to slowing disease progression, apart from current renin-angiotensin-aldosterone system inhibition therapy \[[@R35],[@R36]\]. There is a clear medical need for new therapies for CKD. In view of this need, the Food and Drug Administration (FDA) has considered new recommendations for kidney outcome measures used in the evaluation of new therapies \[[@R21]\]. The FDA accepts a 57% decline in eGFR, corresponding to a doubling of serum creatinine, as an endpoint for clinical trials of kidney disease progression because it represents a marked loss of kidney function that is predictive of eventual kidney failure. Recent initiatives coordinated by the National Kidney Foundation and the FDA are evaluating alternative endpoints to shorten the duration of clinical trials, reduce sample size, and include patients with earlier stages of CKD. Based on a series of meta-analyses of cohorts and clinical trials, as well as simulations of trial designs and analytic methods, these efforts have shown that an eGFR decline of 40% is an acceptable surrogate endpoint to assess treatment effects of new therapies designed to slow CKD progression \[[@R22]--[@R24]\]. It is instructive then to see how this endpoint might be used in light of the prospective studies reported above.

Post hoc analyses of the reported data in selected studies show a relationship between changes in serum HCO~3~ and eGFR decline. For example, subject-level data on changes in serum HCO~3~ and eGFR from the study by Phisitkul *et al.*\[[@R17]\] were evaluated (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). Analysis of these data showed that during the 2-year treatment period, patients in the sodium citrate-treated group (*N* = 30) had a mean (± SD) increase in serum HCO~3~ of 3.27 ± 1.00 mEq/l, whereas those untreated (*N* = 29) had a decrease in serum HCO~3~ of −0.90 ± 0.64 mEq/l (Table [2](#T2){ref-type="table"}), with the difference between groups reaching a high level of significance at the end of the treatment period (*P* \< 0.0001). Within the sodium citrate group, 10.0, 63.3, and 26.67% of the patients had serum HCO~3~ values that increased by less than 2 mEq/l, 2 to less than 4 mEq/l, and at least 4 mEq/l, respectively, during the 2-year treatment period. In contrast, all patients without sodium citrate treatment had serum HCO~3~ increases less than 2 mEq/l during the 2-year treatment period. In the evaluation of eGFR change within the sodium citrate and no sodium citrate treatment groups, significant benefit was seen with sodium citrate over the 2-year treatment period. The mean (± SD) change in eGFR was −3.2 ± 1.45 ml/min/1.73 m^2^ for the sodium citrate treatment group, whereas the control group had a significantly larger (*P* \< 0.0001) mean (± SD) decline in eGFR of −7.59 ± 3.26 ml/min/1.73 m^2^ (Table [3](#T3){ref-type="table"}). Notably, 27.59% (*N* = 8) of the patients in the control group had at least a 40% decline in eGFR over the 2-year treatment period, whereas none of the patients in the sodium citrate treatment group had an eGFR decline of this magnitude. Thus, this post hoc analysis of patient-level data from the Phisitkul *et al.*\[[@R17]\] study demonstrated that significant increases in serum HCO~3~ in CKD patients with metabolic acidosis reduced the likelihood of reaching the clinical endpoint of at least 40% eGFR decline.

Based on data provided in four of the prospective studies that enrolled CKD stage 3--5 patients with overt metabolic acidosis (serum HCO~3~ \<22 mEq/l) \[[@R15],[@R16]^▪▪^,[@R17],[@R18]^▪▪^\], it is possible to calculate an event rate corresponding to initiation of dialysis or kidney transplant or at least 40% reduction of eGFR. In this analysis, the difference between the treatment and control groups in the increase in serum HCO~3~ from the beginning to the end of the treatment period ranged from 4 to 6.8 mEq/l (Fig. [1](#F1){ref-type="fig"}a). The corresponding difference in eGFR decline between the treatment and control groups was between 4.0 and 4.2 ml/min/1.73 m^2^ over the 6--24-month treatment durations (Fig. [1](#F1){ref-type="fig"}b). Further, the change in serum HCO~3~ of 4--6.8 mEq/l corresponded with a reduction in the observed kidney event rate of between 51 and 100% in the treated groups as compared to the control groups over the four studies (Fig. [2](#F2){ref-type="fig"}). Taken together, these four prospective studies provide strong evidence that raising serum HCO~3~ in CKD patients with metabolic acidosis significantly improves clinical outcomes.

CONCLUSION
==========

The importance of normalizing serum HCO~3~ in CKD patients with metabolic acidosis is reflected in the leading treatment guidelines for CKD. The US-based National Kidney Foundation\'s KDOQI guidelines state that serum HCO~3~ levels should be maintained at 22 mEq/l or greater and recommend the use of oral alkali supplements to attain this goal, whereas maintaining an awareness of the complications related to the use of such supplements \[[@R6]\]. Similarly, guidelines from KDIGO suggest that in patients with CKD and serum bicarbonate less than 22 mEq/l treatment with oral bicarbonate supplementation can be given to maintain serum bicarbonate within the normal range unless contraindicated \[[@R5]\]. Several large retrospective database analyses \[[@R7]--[@R10]\] show that clinical outcomes for CKD patients with serum HCO~3~ levels that are below normal (i.e., \<22 mEq/l) are significantly worse compared with patients with normal serum HCO~3~ (i.e., 22--29 mEq/l). In addition, several single-center, prospective studies examining the effects of sodium bicarbonate, sodium citrate, or dietary interventions have also elucidated the beneficial effects of treating chronic metabolic acidosis \[[@R15],[@R16]^▪▪^,[@R17],[@R18]^▪▪^,[@R19],[@R20],[@R34]\]. In four of the seven key interventional studies discussed here, the provision of oral bicarbonate supplementation increased serum HCO~3~ in enrolled CKD patients with baseline serum HCO~3~ less than 22 mEq/l, often within 6 months of treatment initiation. Further, long-term treatment of metabolic acidosis (1--3 years) or treatment of hypertension-associated nephropathy patients with normal serum HCO~3~ belying an increased acid load (5 years), showed direct benefit on reducing eGFR decline and improving kidney outcomes. Importantly, these improvements were accompanied by a reduction in the expression of urine biomarkers that reflect continued injury to kidneys exposed to chronic acid loading. A post hoc analysis of data from the Phisitkul *et al.*\[[@R17]\] study showed that the provision of oral alkali to CKD patients with metabolic acidosis reduced the number of patients who experienced at least 40% decline in eGFR, an accepted surrogate endpoint of kidney disease progression to ESKD \[[@R21]--[@R24]\]. Although 27.6% of control patients in this study showed at least 40% decline in eGFR over the 2-year treatment interval, no patients in the sodium citrate treatment group experienced eGFR declines of this magnitude (Table [3](#T3){ref-type="table"}; Fig. [2](#F2){ref-type="fig"}). A limitation of the studies reviewed here is in the enrollment of patients who did not have severe comorbidities commonly found in CKD (e.g., edema, heart failure, poorly-controlled hypertension), as treatment with sodium-based oral alkali might aggravate fluid homeostasis in such patients \[[@R37]^▪▪^\]. Based on these findings, it seems likely that nutritional and pharmacologic management of metabolic acidosis preserves kidney function, and larger scale, multicenter testing of this hypothesis is warranted.
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Studies of oral bicarbonate supplementation demonstrate slowing of chronic kidney disease progression

  Reference        Study population (CKD stage and serum HCO~3~ level)                                                       Key exclusion criteria                                                                                                                                                                                                                                                                                                                                         Study treatment(s)                                                                                                            Treatment duration                                                        Clinical evidence of treatment effect
  ---------------- --------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------
  \[[@R15]\]       Patients (*N* = 134) with stage 4/5 CKD and serum HCO~3~ \>16 to \<20 mEq/l                               Poorly controlled BP (\>150/90 mmHg despite use of four agents); overt congestive heart failure; malignant disease; morbid obesity; cognitive impairment; chronic sepsis                                                                                                                                                                                       Sodium bicarbonate (1.82 ± 0.80 g/day[^a^](#TF1-1){ref-type="table-fn"}) or no treatment (standard of care)                   2 years                                                                   Sodium bicarbonate slowed the rate of GFR decline and progression to end-stage kidney disease
  \[[@R16]^▪▪^\]   Patients (*N* = 207) with stable stage 4/5 CKD and serum HCO~3~ ∼16--18 mEq/l                             Patients with poorly controlled BP (≥145/85 mmHg), relevant comorbidities (diabetes, heart failure, hepatic disease, digestive diseases), uremic complications (pericarditis, polyneuropathy), or feeding inability (anorexia, nausea)                                                                                                                         Very low-protein diet (VLPD; 0.3 g/kg/day, ketoanalogue supplemented) or low-protein diet (LPD; 0.6 g/kg/day)                 18 months (3-month LPD run-in; 15-months treatment after randomization)   The VLPD slowed the rate of GFR decline and progression to end-stage kidney disease
  \[[@R17]\]       Patients (*N = *59) with Stage 3/4 CKD because of hypertensive nephropathy and serum HCO~3~ \<22 mEq/l    Known primary kidney disease, diabetes, or fasting blood glucose \>110 mg/dl, malignancy, chronic infection, clinical evidence of cardiovascular disease, peripheral edema, heart/liver failure or nephrotic syndrome, renal artery stenosis or primary hyperaldosteronism                                                                                     Sodium citrate (1 mEq/kg bicarbonate equivalent per day) or no treatment (standard of care)                                   2 years                                                                   Sodium citrate slowed the rate of eGFR decline and decreased urine biomarkers of kidney injury (ET-1, NAG, albumin, TGF-β)
  \[[@R18]^▪▪^\]   Patients (*N* = 188) with CKD stage 3/4 and serum bicarbonate \<22 mEq/l                                  Patients with structural or functional anomalies of the gastrointestinal tract; decompensated chronic liver disease; decompensated heart failure; morbid obesity (BMI ≥40 kg/m^2^); malignancy; chronic infections; prior bicarbonate therapy for a duration of \>2 weeks; receiving immunosuppression therapy                                                 Sodium bicarbonate (2.3 g/day) or no treatment (standard of care)                                                             6 months                                                                  Sodium bicarbonate slowed the rate of GFR decline and was associated with preservation of lean body mass and mid-arm muscle circumference
  \[[@R19]\]       Patients (*N* = 71) with stage 4 CKD because of hypertensive nephropathy and serum HCO~3~ \<22 mEq/l      Known primary kidney disease, diabetes or fasting blood glucose ≥110 mg/dl, malignancy, chronic infection, clinical evidence of cardiovascular disease, peripheral edema, heart/liver failure or nephrotic syndrome, plasma potassium level \>4.6 mEq/l; taking or inability to stop taking drugs (other than ACE inhibitors) that limit potassium excretion   Sodium bicarbonate (1 mEq/kg/day) or fruits/vegetables to reduce dietary acid by 50%                                          1 year                                                                    Both sodium bicarbonate and dietary fruits and vegetables decreased urine biomarkers of kidney injury (albumin, NAG, and TGF-β)
  \[[@R20]\]       Patients (*N* = 108) with stage 3 CKD because of hypertensive nephropathy and serum HCO~3~ 22--24 mEq/l   Known primary kidney disease, diabetes or fasting blood glucose ≥110 mg/dl, malignancy, chronic infection, clinical evidence of cardiovascular disease, peripheral edema, heart/liver failure or nephrotic syndrome, plasma potassium level \>4.6 mEq/l; taking or inability to stop taking drugs (other than ACE inhibitors) that limit potassium excretion   Sodium bicarbonate (0.3 mEq/kg/day), or fruits/vegetables to reduce dietary acid by 50%, or no treatment (standard of care)   3 years                                                                   Both sodium bicarbonate and fruits/vegetables slowed the rate of eGFR decline and decreased urine biomarkers of kidney injury (albumin, NAG angiotensinogen)
  \[[@R34]\]       Patients (*N* = 120) with stage 2 CKD because of hypertensive nephropathy and serum HCO~3~ ∼26 mEq/l      Known primary kidney disease, diabetes or fasting blood glucose \>110 mg/dl, malignancy, chronic infection, clinical evidence of cardiovascular disease, peripheral edema or heart failure, smoking or oral tobacco use                                                                                                                                        Sodium bicarbonate (0.5 mEq/kg/day) or sodium chloride (0.5 mEq/kg/day) or placebo                                            5 years                                                                   Sodium bicarbonate slowed the rate of eGFR decline and decreased urine biomarkers of kidney injury (ET-1, albumin, NAG)

ACE, angiotensin-converting enzyme; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ET-1, endothelin-1; HCO~3~, bicarbonate; LPD, low protein diet; NAG, N-acetyl-β-D-glucosaminidase; RRT, renal replacement therapy; TGF-β, transforming growth factor β; VLPD, very low-protein diet.

^a^Mean (SD).

###### 

Mean serum bicarbonate (mEq/l) change from baseline over 24-month treatment period comparing sodium citrate and no sodium citrate groups

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                Sodium citrate group (*N* = 30)   No sodium citrate (*N* = 29)   *P* value
  ----------------------------------------------------------------------------- --------------------------------- ------------------------------ -----------
  Baseline[^a^](#TF2-1){ref-type="table-fn"}                                    20.78 (1.17)\                     20.55 (0.79)\                  0.3745
                                                                                17.2--23.7                        18.6--21.6                     

  Month 6[^a^](#TF2-1){ref-type="table-fn"}                                     20.53 (1.14)\                     20.50 (0.80)\                  0.9175
                                                                                17--22.2                          19--21.8                       

  Month 30[^a^](#TF2-1){ref-type="table-fn"}                                    23.80 (0.96)\                     19.60 (1.17)\                  \<0.0001
                                                                                20.8--25.4                        17.3--21.2                     

  Change (month 30--month 6)[^a^](#TF2-1){ref-type="table-fn"}                  3.27 (1.00)\                      −0.90 (0.64)\                  \<0.0001
                                                                                1.4--5.1                          −2.2--0.3                      

  \% change (month 30--month 6)[^a^](#TF2-1){ref-type="table-fn"}               16.16% (5.47%)\                   −4.45% (3.21%)\                \<0.0001
                                                                                6.45--25.63%                      −10.63--1.49%                  

  \<2 mEq/l change[^b^](#TF2-2){ref-type="table-fn"} (month 6 to month 30)      3 (10%)                           29 (100%)                      

  2--\<4 mEq/l change[^b^](#TF2-2){ref-type="table-fn"} (month 6 to month 30)   19 (63.33%)                       0                              

  ≥4 mEq/l change[^b^](#TF2-2){ref-type="table-fn"} (month 6 to month 30)       8 (26.67%)                        0                              
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Values are mean (SD); minimum to maximum.

^b^Values are number (percentage).

Adapted with permission from \[[@R17]\].

###### 

Mean eGFR (ml/min/1.73 m^2^) change from baseline over 24-month treatment period comparing sodium citrate and no sodium citrate groups

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                               Sodium citrate group (*N* = 30)   No sodium citrate (*N* = 29)   *P* value
  ---------------------------------------------------------------------------- --------------------------------- ------------------------------ -----------
  Baseline[^a^](#TF3-1){ref-type="table-fn"}                                   33.02 (8.48)\                     33.38 (8.39)\                  0.8706
                                                                               18--57.6                          19--49                         

  Month 6[^a^](#TF3-1){ref-type="table-fn"}                                    32.67 (8.21)\                     32.52 (8.33)\                  0.9449
                                                                               18--56                            18--47                         

  Month 30[^a^](#TF3-1){ref-type="table-fn"}                                   29.47 (8.77)\                     24.93 (9.74)\                  0.0656
                                                                               14--52                            10--44                         

  Change (month 30--month 6)[^a^](#TF3-1){ref-type="table-fn"}                 −3.2 (1.45)\                      −7.59 (3.26)\                  \<0.0001
                                                                               −6 to 0                           −17 to −2                      

  \% Change (month 30--month 6)[^a^](#TF3-1){ref-type="table-fn"}              −10.82% (6.44%)\                  −25.72% (13.84%)\              \<0.0001
                                                                               −24 to 0%                         −53.13 to −4.35%               

  ≥40% decrease eGFR[^b^](#TF3-2){ref-type="table-fn"} (month 6 to month 30)   0                                 8 (27.59%)                     
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

eGFR, estimated glomerular filtration rate.

^a^Values are mean (SD); minimum to maximum.

^b^Values are number (percentage).

Adapted with permission from \[[@R17]\].
